Novo Nordisk has filed a lawsuit against US telehealth company Hims & Hers, accusing it of selling unauthorized versions of its popular weight-loss medications. The Danish pharmaceutical giant is seeking to block the sale of these so-called 'knock-off' drugs, which allegedly mimic Novo Nordisk's semaglutide-based treatments like Wegovy.

The legal action comes amid growing competition in the anti-obesity drug market, where Novo Nordisk faces increasing pressure from both legitimate competitors and potential copycats. The company has already warned investors about potential price cuts in the crowded market for weight-loss medications, which could impact its bottom line.

This lawsuit represents a significant move by Novo Nordisk to protect its intellectual property and market share in the lucrative weight-loss drug segment. The outcome could have broader implications for how pharmaceutical companies defend their patented medications against unauthorized versions sold through telehealth platforms. The case highlights the growing tensions between traditional pharmaceutical companies and newer digital health providers in the rapidly expanding weight-loss drug market.